Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee
Conditions
Interventions
REGN5069
Matching Placebo
Locations
12
United States
Regeneron Study Site
DeLand, Florida, United States
Regeneron Study Site
Jupiter, Florida, United States
Regeneron Study Site
Miami, Florida, United States
Regeneron Study Site
Charleston, South Carolina, United States
Regeneron Study Site
Tbilisi, Georgia
Regeneron Study Site
Chisinau, Moldova
Start Date
May 21, 2019
Primary Completion Date
May 1, 2020
Completion Date
October 29, 2020
Last Updated
July 1, 2021
NCT06346132
NCT07482709
NCT07351968
NCT06946290
NCT07041736
NCT06528288
Lead Sponsor
Regeneron Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions